knowledge -WSS

knowledge

author：entertainment 2025-09-03 07:36:22 - browse：63

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Churchill Downs extends trainer Bob Baffert's ban through 2024

leisure time

WSS

Tome Biosciences co

Resistance to opioid

Kremlin open to talks over potential prisoner swap involving detained US reporter Evan Gershkovich

The Democratic Party promised to overhaul its primaries. Doing that has been anything but simple

Abbott's new heart device gets FDA advisory panel nod

Churchill Downs extends trainer Bob Baffert's ban through 2024

Wikipedia

knowledge

focus

Wildfire smoke exposes gaps in outdoor worker protections

Churchill Downs extends trainer Bob Baffert's ban through 2024

Peter Hotez and the public health issue of online harassment

Resistance to opioid

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Masked assailants attack a journalist and a lawyer in Russia's Chechnya province

Hollywood unions extend contract negotiations for actors

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

Moonlake's readout produced a cash windfall. Risks remain

Juul documents reveal insider tactics on political lobbying

focus

STAT Boddities: What happens to the brain when we get scared?

Some in Scotland's Orkney Islands want to return to Norway after 550 years

July 4th fireworks can be stressful for dogs. These 6 tips can keep them calm and safe

Congress might make insulin pumps more accessible to the blind

Study gives hint on South Asians’ higher risk of cardiovascular disease

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

knowledge

leisure time

knowledge

entertainment